Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Fully biologically active when compared to standard. The ED50 as determined by its ability to induce apoptosis using human TF-1 cells is less than 20 ng/ml, corresponding to a specific activity of > 5.0 × 104 IU/mg.
Lyophilized from 0.2 µm filtered PBS, pH 7.4, 0.02% Tween20
Reconstitute in sterile distilled water to 0.1-1 mg/ml.
Long term: -80°C; Short term: -20°C. Avoid freeze-thaw cycles.
TNFSF15 / TL1A / VEGI is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF and IL-1 alpha. This cytokine is a ligand for receptor TNFRSF25 and decoy receptor TNFRSF21/DR6. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells.